GEN Exclusives

More »

Feature Articles

More »
May 1, 2012 (Vol. 32, No. 9)

Advancing Beyond the Genome with Affinity Proteomics

  • Until recently, the field of disease proteomics was focused on separation techniques coupled with mass-spectrometric identification of proteins. However, technological limitations due to patient-to-patient variability and loss of signal from low-abundance proteins have lead researchers to a different technique: affinity proteomics.

    Based on the use of capture reagents such as antibodies, affinity proteomics has emerged as a tool capable of gathering information on the global level in a high-throughput format. In the last 10 years, antibody microarray technology rapidly evolved from proof-of-concept to state-of-the-art technology capable of targeting complex, nonfractionated protein samples.

    Multiple versions of affinity reagents are deployed in this space, including full-length antibodies, aptamers, affibody molecules, and single-chain variable fragments of antibodies. Various capture formats are also being explored, ranging from planar arrays (similar to commonly used printed DNA arrays) to beads, to direct synthesis of antibodies in the array format.

    Affinity arrays are rapidly emerging as powerful biomarker discovery tools and have become key topics for discussion at biotech conferences worldwide. Antibody-based proteomics has already delivered multiple specific biomarker candidates, and many of those are being translated into clinical practice.

    “The field of disease proteomics is in agreement that a clinical state is more likely to be described by a complex protein signature rather than a single biomarker,” says Christer Wingren, Ph.D., associate professor, CREATE Health and department of immunology, Lund University.

    “Under the assumption that the immune system is highly sensitive to changes in health, like a sensor, we decided to focus on inflammatory and immunoregulatory proteins,” continues Dr. Wingren, who spoke at the Select Biosciences Advances in Microarray Technology meeting in March in Edinburgh.

    “Our arrays combine molecules commonly associated with immune system regulations, but their combinations, or signatures, are unique to each disease. Moreover, these signatures seem to be robust enough to cope with population biological variability.”

    Dr. Wingren’s team worked closely with clinicians to determine unmet clinical needs that could be addressed by serum proteomics. Systemic lupus erythromatosis (SLE) is a severe autoimmune disease, diagnosed on the basis of multiple clinical criteria. A more precise diagnosis of SLE, including classifying it in categories and predicting the onset of flare, would enable rheumatologists to optimize therapy accordingly.

    “We also had to adapt our technology to a common clinical format, which means using crude unfractionated blood samples,” continues Dr. Wingren. “Our cross-disciplinary approach led to simultaneous optimization of all major array parameters, including antibody design, array surface, sample handling, array detection, and bioinformatic analysis, which has turned out to be essential in our efforts to design a state-of-the-art antibody array platform.”

    The team used well-characterized single-chain antibody fragments directed against a few hundred key analytes involved in immunoregulation. Serum proteome profiles revealed SLE-specific inflammatory portraits. Moreover, the signatures were able to differentiate between phenotypic subsets of SLE, as well as between states of flare and remission.

    Immunovia, a Lund University spin-off, will continue to validate and commercialize diagnostic tests based on the immune signatures. Notably, Dr. Wingren says he and his team have also made significant progress in defining cancer-associated biomarker signatures using the same technology platform.

  • Inflammatory Signaling Pathways

    Click Image To Enlarge +
    RayBiotech’s Quantibody Multiplex ELISA Antibody Arrays provide quadruplicate data points to accurately measure the concentrations of up to 40 proteins simultaneously in 100 µL of sample. The array map depicted here is for the Human Quantibody Th1/Th2 Cytokine Array.

    RayBiotech specializes in cytokine antibody arrays. “Complex questions of disease biology cannot be answered using a single array platform,” comments Brett Burkholder, manager, marketing and technical support. “We provide our customers with multiple complementary choices that enable them to approach the problem from all angles.

    “RayBiotech Quantibody®7000 sandwich-based array offers global profiling of 320 unique proteins related to cytokine signaling. Our targeted arrays help to narrow down specific signaling pathways. Even more focused arrays, such as the T-helper array, allows researchers to identify cell functions via cytokine expression profiles.”

    RayBiotech antibody arrays are used for probing disease processes, particularly when only a few details are known. For example, use of a broad screening array confirmed the long-suspected role of inflammation in autism by detecting high expression of inflammatory cytokines in brains of autistic patients.

    “We are committed to making our technology valuable for biomarker discovery and validation,” Burkholder continues. “In a benchmark study, RayBiotech’s C-1000 120-cytokine screening array was used to profile plasma from patients with the confirmed Alzheimer disease diagnosis and from matched controls.”

    Prediction analysis and cross-validation established an 18-marker signature, which was able to correctly predict clinical diagnosis of Alzheimer disease with 89% accuracy, Burkholder claims. “Cytokine biology is exceedingly complex, and we are yet to exhaust discovery opportunities in this space,” he says.

    “We are not just a supplier for biomarker discovery, we are a partner,” he adds. The company supports biomarker discovery efforts on its platform through a grant program. RayBiotech also offers biostatistics and bioinformatics support, and provides comprehensive testing and validation services.

    RayBiotech, which was on the program at the St. John’s University Biotechnology Colloquium last month, has even published its own biomarker research, in which human proteins were screened simultaneously in samples of patients with ovarian cancer and of normal subjects. The five-marker cytokine signature identified via the screen is now being validated by quantitative antibody arrays. The firm believes that this and other affinity signatures hold a promise of early diagnosis of cancer, when the treatment is most effective.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?